
|Articles|November 2, 2012
Similar bleeding rates seen with two anticoagulants
Bleeding rates associated with new use of dabigatran (Pradaxa, Boehringer Ingelheim) do not appear to be higher than bleeding rates associated with new use of warfarin, according to an FDA safety review of post-market reports of serious bleeding events.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Opioid Overdose Deaths Fall by 34% in 2025 | ASHP Midyear 2025
2
Expert Discusses Cannabinoid Adverse Effects | ASHP Midyear 2025
3
Pharmacists Must Consider Benefits and Risks for GLP-1 Medication for Pediatric Patients | ASHP Midyear 2025
4
Centralized IV Compounding Drives Pharmacy Savings, Efficiency | ASHP Midyear 2025
5



































































































































